Ionis Pharmaceuticals Inc at Needham Healthcare Conference Transcript
Good afternoon, everyone. Thanks for joining us. My name is Chad Messer. I'm a senior biotech analyst here at Needham & Company. I'm joined today by Beth Hougen, Chief Financial Officer; and Wade Walke, Vice President of Investor Relations at Ionis Pharmaceuticals. And I'm going to hand it to Beth to get it started.
Great. Thank you. Thank you for having us. We have been on a roll lately. It's been just an exciting time at Ionis. We have 2 drugs that are commercial now: SPINRAZA and TEGSEDI, both for rare diseases, both fatal rare diseases. And WAYLIVRA, our third drug should be approved here in Europe within the next couple of months or so. So a very exciting time in that we're building our financial story with commercial revenues now. Our pipeline continues to perform. We have 4 drugs that will be in pivotal studies this year. Two already have started, one for Huntington's and one for SOD1, and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |